Discussing axSpA: Long-term safety and efficacy of Bimekizumab results from BE-AGILE & BE-MOBILE 1/2

Information

Show

The IMID Forum

Published

February 27, 2025

Type

audio

Language

EN

Author

The Immune-Mediated Inflammatory Disease Forum

Categories

education